Found: 12
Select item for more details and to access through your institution.
Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin Combined With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive, Early-Stage Breast Cancer.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Randomized phase-II evaluation of letrozole plus dasatinib in hormone receptor positive metastatic breast cancer patients.
- Published in:
- NPJ Breast Cancer, 2019, v. 5, n. 1, p. N.PAG, doi. 10.1038/s41523-019-0132-8
- By:
- Publication type:
- Article
Erratum to: Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer.
- Published in:
- 2014
- By:
- Publication type:
- Erratum
Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2014, v. 146, n. 2, p. 321, doi. 10.1007/s10549-014-2923-9
- By:
- Publication type:
- Article
Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2011, v. 126, n. 1, p. 101, doi. 10.1007/s10549-010-1286-0
- By:
- Publication type:
- Article
Results of a phase II open-label, nonrandomized trial of oral satraplatin in patients with metastatic breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2010, v. 118, n. 2, p. 361, doi. 10.1007/s10549-009-0410-5
- By:
- Publication type:
- Article
Five‐year results of a phase II trial of preoperative 5‐fluorouracil, epirubicin, cyclophosphamide followed by docetaxel with capecitabine (wTX) (with trastuzumab in HER2‐positive patients) for patients with stage II or III breast cancer
- Published in:
- Cancer Medicine, 2018, v. 7, n. 6, p. 2288, doi. 10.1002/cam4.1472
- By:
- Publication type:
- Article
Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling.
- Published in:
- BMC Research Notes, 2013, v. 6, n. 1, p. 1, doi. 10.1186/1756-0500-6-507
- By:
- Publication type:
- Article
Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer.
- Published in:
- 2019
- By:
- Publication type:
- journal article
A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma.
- Published in:
- American Journal of Hematology, 2017, v. 92, n. 5, p. 460, doi. 10.1002/ajh.24687
- By:
- Publication type:
- Article
Efficacy and Safety of Weekly Paclitaxel With or Without Oral Alisertib in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial.
- Published in:
- JAMA Network Open, 2021, v. 4, n. 4, p. e214103, doi. 10.1001/jamanetworkopen.2021.4103
- By:
- Publication type:
- Article
Evaluation of Miracle Mouthwash plus Hydrocortisone Versus Prednisolone Mouth Rinses as Prophylaxis for Everolimus‐Associated Stomatitis: A Randomized Phase II Study.
- Published in:
- Oncologist, 2019, v. 24, n. 9, p. 1153, doi. 10.1634/theoncologist.2018-0340
- By:
- Publication type:
- Article